Evidence-Based Complementary and Alternative Medicine

Evidence-Based Complementary and Alternative Medicine / 2005 / Article

Original Article | Open Access

Volume 2 |Article ID 656528 | https://doi.org/10.1093/ecam/neh103

Gholamreza Karimi, Mohammad Ramezani, Zahra Tahoonian, "Cisplatin Nephrotoxicity and Protection by Milk Thistle Extract in Rats", Evidence-Based Complementary and Alternative Medicine, vol. 2, Article ID 656528, 4 pages, 2005. https://doi.org/10.1093/ecam/neh103

Cisplatin Nephrotoxicity and Protection by Milk Thistle Extract in Rats

Received03 Apr 2005
Accepted03 Jul 2005

Abstract

The protective effect of methanolic extract of milk thistle seeds and silymarin against cisplatin-induced renal toxicity in male rats after a single intraperitoneal injection of 3 mg kg−1 cisplatin were studied. Over 5 days, cisplatin-treated rats showed tubular necrosis and elevation in blood urea nitrogen (BUN) and serum creatinine (Scr). Pretreatment of animals with silymarin (50 mg kg−1) or extract (0.6 g kg−1) 2 h before cisplatin prevented the tubular damage. Rats treated with silymarin or extract 2 h after cisplatin had BUN and Scr significantly lower than those receiving cisplatin, but mild to moderate necrosis was observed. These results suggested that milk thistle may protect against cisplatin-induced renal toxicity and might serve as a novel combination agent with cisplatin to limit renal injury.

Copyright © 2005 Gholamreza Karimi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Order printed copiesOrder
Views145
Downloads779
Citations

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.